A phase 3 randomized, observer-blind, controlled study to evaluate the immunogenicity, reactogenicity and safety of an mRNA-based seasonal influenza vaccine, in adults 18-64 years of age

Influenza, Human

•HI titers at Day 29 •NI titers at Day 29 •HI seroconversion from baseline to Day 29, Solicited AEs • Occurrence of any solicited administration site and systemic events during the 7 days following study intervention administration. Unsolicited AEs • Occurrence of unsolicited AEs during the 28 days following study intervention administration. MAAEs, SAEs and AESIs • Occurrence of SAEs and AESIs up to 6 months following study intervention administration.

• HI titers at Day 29 • HI seroconversion from baseline to Day 29, • Fold increase in HI titers at Day 29 relative to baseline • HI seroprotection at baseline and Day 29 • NI titers at Day 29 • Fold increase in NI titers at Day 29 relative to baseline • NI seroconversion from baseline to Day 29 • Virus neutralization titers at Day 29 by MN assay • Fold increase in virus neutralization titers at Day 29 relative to baseline • Virus neutralization seroconversion from baseline to Day 29

No related papers found yet.